Advertising Medical Devices in Thailand: Thai FDA Approval Rules

A registered medical device and an approved marketing campaign are two separate regulatory milestones in Thailand, and companies that treat the second as a formality after clearing the first tend to find out the hard way that Section 57 of the Medical Device Act B.E. 2551 (2008) works in a fixed order: approval first, publication second. A company that runs an advertisement and submits it for approval afterward is already in violation the moment the ad goes live, regardless of how strong the underlying registration is.

Section 57 and what it actually requires

The Medical Device Act B.E. 2551 (2008), as amended by the B.E. 2562 (2019) amendment, gives the Medical Devices Control Division (MDCD) authority over both device registration and device promotion. Section 57 prohibits advertising a medical device to the general public without prior written Thai FDA approval, and the prohibition is genuinely prospective: publish first and seek approval after, and the violation has already occurred. This obligation resets with every meaningful change, too. A revision to approved advertising content, whether it's a new claim, a new image, or a new medium, restarts the approval requirement rather than extending the original clearance.

The 2019 amendment specifically closed what had been a real grey area around digital media. Regulators now treat Thai-language online content aimed at Thai consumers the same as print and broadcast advertising, which ended a period where some market participants had treated digital as outside the Act's reach.

What actually counts as advertising

The Act defines advertising broadly: any communication directed at the general public that promotes, commends, or draws attention to a device's use, quality, safety, or efficacy counts, and the channel doesn't change the classification. Print and broadcast placements (newspaper, magazine, TV, radio, billboards) were the original target of the 2008 text. Digital and online content is treated the same way now: websites, banner ads, search engine marketing, email campaigns, and any digital content accessible to Thai users falls under the Act, and Thai-language social media accounts run by a manufacturer or local distributor count as advertising channels whether the posts are paid or organic. Physical promotional materials, meaning brochures, product leaflets, point-of-sale displays, and trade fair booth materials distributed to or visible by the general public, also require prior approval. Influencer and third-party content commissioned or sponsored by a manufacturer or distributor is treated as advertising too; calling the arrangement an "editorial partnership" doesn't change how MDCD classifies it.

One useful clarification: device labeling, including the packaging insert and instructions for use, is governed separately under the Act's labeling provisions and isn't classified as advertising. Labeling compliance is a precondition of registration itself, not a post-registration promotional matter, and the two obligations run in parallel without overlapping.

Where HCP communications sit differently

MDCD draws a real distinction between advertising to the general public and scientific or promotional communications aimed exclusively at licensed healthcare professionals. Articles in peer-reviewed medical journals, presentations at accredited medical conferences, and direct communication from medical science liaisons to individual clinicians generally count as professional communications rather than public advertising, and they don't require the same pre-approval pathway a consumer campaign does. That doesn't make them unregulated, though: every claim in any communication, regardless of audience, still has to be truthful, non-misleading, and consistent with the device's approved intended use and indications.

A company can't use an HCP channel as a workaround for claims that wouldn't survive general public review. Promotional materials left where patients might encounter them in a clinic or hospital, or content on a professional-facing platform that's also accessible to the general public, can revert to the general public advertising classification if MDCD concludes the foreseeable audience includes lay consumers.

What MDCD requires in the approval application

The advertising approval application goes to MDCD and has to be complete before the advertisement runs; incomplete submissions are returned without substantive review, restarting the clock entirely. MDCD requires the advertising content itself in final or near-final form (finished artwork and copy for print or digital, a script and storyboard for a video or broadcast spot with the final cut confirmed before air, full-page mockups for online content); the device's current Thai FDA registration certificate, since advertising an unregistered or lapsed-registration device is a separate and more serious violation than advertising without approval; and a signed claims-to-labeling correspondence statement confirming every claim in the advertisement matches the approved intended use and labeling on file. Claims exceeding the registered intended use aren't approvable regardless of what clinical evidence the manufacturer holds internally. Review timelines vary by device category and submission volume, and building that review window into campaign planning up front avoids treating it as an afterthought that can be rushed at the last minute.

Claims that will never get approved

Even a properly constituted application with a valid registration certificate attached will not get approval for certain categories of claims, and submitting them anyway invites additional scrutiny of the applicant's broader compliance posture. Claims that a device treats, cures, or prevents conditions outside its approved intended use are prohibited outright; a device registered for wound closure can't advertise antimicrobial efficacy unless that property was part of the registered indication reviewed at registration, and expanding claimed indications requires a variation to the registration file first. Before-and-after comparisons need clinical substantiation reviewed as part of registration or post-market follow-up; anecdotal social media images don't qualify. Testimonials implying guaranteed outcomes are barred, so phrases like "guaranteed results" or framing a single case as a typical outcome will block approval. Named-competitor price comparisons are prohibited regardless of whether the underlying price data is accurate.

Enforcement and the cost of getting this wrong

The penalty for advertising a medical device without a prior licence is imprisonment for up to six months or a fine of up to 50,000 THB, or both, under Section 116 of the Act, and each advertisement, in some cases each individual publication or broadcast of it, can constitute a separate violation. Repeated violations, or ones involving false or misleading claims, can escalate to suspension or revocation of the device's registration and import license. Enforcement has genuinely increased since the 2019 amendment, with MDCD coordinating with the Electronic Transactions Development Agency (ETDA) on monitoring Thai-language digital channels and using platform takedown requests alongside administrative fines. Foreign-language materials built exclusively for export markets, hosted internationally and not distributed within Thailand, generally fall outside MDCD's jurisdiction, since the threshold is whether the material is directed at or accessible to Thai consumers as its intended audience, not simply whether it exists online somewhere.

Companies that discover past non-compliance in their own advertising history are generally better off disclosing and remediating voluntarily than waiting for a formal enforcement notice. DeeMED Consulting works with foreign manufacturers and their Thai local license holder to build advertising approval into the campaign timeline from the start, so consumer and HCP materials clear MDCD before anything runs, not after.